Related Experiment Video
Updated: Oct 15, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Atrial Cardiomyopathy: Pathophysiology and Clinical Consequences
Andreas Goette1,2, Uwe Lendeckel3
1Department of Cardiology and Intensive Care Medicine, St. Vincenz Hospital, 33098 Paderborn, Germany.
Insights
Atrial fibrillation (AF) affects millions globally, often linked to atrial cardiomyopathy. Understanding AF pathophysiology, including oxidative stress, inflammation, diabetes, and obesity, is key to preventing strokes.
Area of Science:
- Cardiology
- Pathophysiology
- Biomedical Science
Background:
- Atrial fibrillation (AF) impacts over 33.5 million people worldwide, with 5 million new cases annually.
- Most AF patients exhibit atrial cardiomyopathy, a condition conceptualized in 2016.
- Therapeutic strategies targeting underlying diseases and atrial tissue remodeling are crucial for AF management.
Purpose of the Study:
- To summarize the pathophysiology and remodeling processes in atrial cardiomyopathy, thrombogenesis, and AF.
- To elucidate the specific roles of oxidative stress, inflammation, diabetes, and obesity in AF development.
Main Methods:
- Literature review and synthesis of existing research on atrial cardiomyopathy.
- Analysis of pathophysiological mechanisms contributing to AF and thrombogenesis.
- Focus on the impact of metabolic and inflammatory factors.
Main Results:
- Atrial cardiomyopathy is a significant factor in AF, involving complex remodeling processes.
- Oxidative stress, inflammation, diabetes, and obesity are identified as key contributors to AF pathophysiology.
- Interventions addressing these factors may reduce thrombogenesis and stroke risk.
Conclusions:
- Effective AF therapy requires addressing underlying atrial cardiomyopathy and associated risk factors.
- Targeting oxidative stress, inflammation, diabetes, and obesity holds therapeutic potential for AF and stroke prevention.
- Further research into these mechanisms can guide novel treatment strategies.
Abstract:
Around the world there are 33.5 million patients suffering from atrial fibrillation (AF) with an annual increase of 5 million cases. Most AF patients have an established form of an atrial cardiomyopathy. The concept of atrial cardiomyopathy was introduced in 2016. Thus, therapy of underlying diseases and atrial tissue changes appear as a cornerstone of AF therapy. Furthermore, therapy or prevention of atrial endocardial changes has the potential to reduce atrial thrombogenesis and thereby cerebral stroke. The present manuscript will summarize the underlying pathophysiology and remodeling processes observed in the development of an atrial cardiomyopathy, thrombogenesis, and atrial fibrillation. In particular, the impact of oxidative stress, inflammation, diabetes, and obesity will be addressed.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Pathophysiology of Heart Failure
Myocarditis I: Introduction
Cardiomyopathy V: Interprofessional Care

